Nuo Therapeutics Inc Share Price OTC Bulletin Board
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-20 | Nuo Therapeutics, Inc. announced that it has received $0.650875 million in funding | CI |
05-15 | Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2022 | 112K 8.82M | Sales 2023 | 609K 47.84M | Capitalization | 24.33M 1.91B |
---|---|---|---|---|---|
Net income 2022 | -3M -236M | Net income 2023 | -3M -236M | EV / Sales 2022 | 543 x |
Net cash position 2022 | 1.72M 135M | Net cash position 2023 | 673K 52.92M | EV / Sales 2023 | 38.9 x |
P/E ratio 2022 |
-18.9
x | P/E ratio 2023 |
-7.3
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 41.29% |
Managers | Title | Age | Since |
---|---|---|---|
David Jorden
CEO | Chief Executive Officer | 61 | 18/09/08 |
Peter Clausen
COO | Chief Operating Officer | 58 | 31/08/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
C. Winzer
BRD | Director/Board Member | 67 | 29/01/09 |
David Jorden
CEO | Chief Executive Officer | 61 | 18/09/08 |
Paul Mintz
BRD | Director/Board Member | 75 | 06/04/17 |
1st Jan change | Capi. | |
---|---|---|
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |